PT1017367E - Metodos para fabricar preparacoes de libertacao controlada baseadas em polimeros - Google Patents

Metodos para fabricar preparacoes de libertacao controlada baseadas em polimeros

Info

Publication number
PT1017367E
PT1017367E PT98947168T PT98947168T PT1017367E PT 1017367 E PT1017367 E PT 1017367E PT 98947168 T PT98947168 T PT 98947168T PT 98947168 T PT98947168 T PT 98947168T PT 1017367 E PT1017367 E PT 1017367E
Authority
PT
Portugal
Prior art keywords
polymer
active agent
solvent
methods
polymers
Prior art date
Application number
PT98947168T
Other languages
English (en)
Inventor
Paul F Herbert
Mark A Tracy
John D Herberger
Paul A Burke
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of PT1017367E publication Critical patent/PT1017367E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
PT98947168T 1997-09-24 1998-09-21 Metodos para fabricar preparacoes de libertacao controlada baseadas em polimeros PT1017367E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/935,452 US5989463A (en) 1997-09-24 1997-09-24 Methods for fabricating polymer-based controlled release devices

Publications (1)

Publication Number Publication Date
PT1017367E true PT1017367E (pt) 2003-10-31

Family

ID=25467166

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98947168T PT1017367E (pt) 1997-09-24 1998-09-21 Metodos para fabricar preparacoes de libertacao controlada baseadas em polimeros

Country Status (11)

Country Link
US (2) US5989463A (pt)
EP (1) EP1017367B1 (pt)
JP (1) JP2001517615A (pt)
AT (1) ATE240718T1 (pt)
AU (1) AU746337B2 (pt)
CA (1) CA2304662C (pt)
DE (1) DE69814885T2 (pt)
DK (1) DK1017367T3 (pt)
ES (1) ES2200375T3 (pt)
PT (1) PT1017367E (pt)
WO (1) WO1999015154A1 (pt)

Families Citing this family (446)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6723517B1 (en) 1998-06-02 2004-04-20 Minerva Biotechnologies Corporation Use of self-assembled monolayers to probe the structure of a target molecule
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6514525B2 (en) 1998-09-10 2003-02-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
EP1074248A1 (en) * 1999-07-08 2001-02-07 Arnold Hilgers Delivery system for biological material
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2398466A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU4002001A (en) * 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
DE60140625D1 (de) 2000-08-15 2010-01-07 Univ Illinois Verfahren zur herstellung von mikropartikeln
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7666445B2 (en) 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU1994402A (en) 2000-11-28 2002-06-11 Mediummune Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US6730772B2 (en) 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
EP1418890B1 (en) * 2001-08-16 2008-05-14 Baxter International Inc. Propellant-based microparticle formulations
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
WO2004010935A2 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
SI1551876T1 (sl) 2002-10-16 2011-07-29 Purdue Pharma Lp Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
KR100709015B1 (ko) * 2002-11-13 2007-04-18 (주)아모레퍼시픽 지속적 약물방출이 가능한 고분자 미립구 및 그 제조방법
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DK1589934T3 (en) 2003-01-06 2015-12-21 Corixa Corp Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
US7736391B2 (en) 2003-02-06 2010-06-15 Tonaba Healthscience Ii, Llc Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis
KR20050115315A (ko) * 2003-03-26 2005-12-07 가부시키가이샤 엘티티 바이오파마 약물 전달 및 서방성 약물 방출을 표적으로 하는 정맥 내 나노입자
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
US7326571B2 (en) * 2003-07-17 2008-02-05 Boston Scientific Scimed, Inc. Decellularized bone marrow extracellular matrix
WO2005035088A2 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
EP2441474B1 (en) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7309500B2 (en) * 2003-12-04 2007-12-18 The Board Of Trustees Of The University Of Illinois Microparticles
US20060053516A1 (en) * 2003-12-05 2006-03-09 The University Of Hong Kong Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization against SARS
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US20050220887A1 (en) * 2004-01-20 2005-10-06 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
RU2376028C2 (ru) 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
PL2409707T3 (pl) 2004-04-15 2015-08-31 Amylin Pharmaceuticals Llc Urządzenie o przedłużonym uwalnianiu na bazie polimeru
CA2566079A1 (en) 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
WO2005112885A2 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1753404A1 (en) 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
CA2574709A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
US7748343B2 (en) 2004-11-22 2010-07-06 The Board Of Trustees Of The University Of Illinois Electrohydrodynamic spraying system
US20060165667A1 (en) * 2004-12-03 2006-07-27 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
WO2006078841A1 (en) * 2005-01-21 2006-07-27 President And Fellows Of Harvard College Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
JP2008539260A (ja) * 2005-04-25 2008-11-13 アムジエン・インコーポレーテツド ポロゲンを含む生分解性プチド徐放性組成物
US8017152B2 (en) 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN103146708A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2947330C (en) 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
WO2007074604A1 (ja) * 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. 水溶性非ペプチド性低分子薬物含有ナノ粒子
US20080058316A1 (en) 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
CA2649915A1 (en) * 2006-04-20 2007-11-01 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US8747870B2 (en) 2006-04-20 2014-06-10 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
MX2008015771A (es) 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US20080075777A1 (en) * 2006-07-31 2008-03-27 Kennedy Michael T Apparatus and methods for preparing solid particles
EP2647712A3 (en) 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
US7763242B2 (en) 2006-09-07 2010-07-27 Scott and White Memorial Hospital Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate
PL3339445T3 (pl) * 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
EP2064335A4 (en) 2006-10-16 2011-03-30 Medimmune Llc MOLECULES WITH REDUCED HALF TIME, COMPOSITIONS AND ITS USE
US20080121733A1 (en) * 2006-11-29 2008-05-29 Donald Ackley Droplet generating device and method
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP4564098B2 (ja) 2006-12-18 2010-10-20 武田薬品工業株式会社 徐放性組成物およびその製造法
WO2008101116A1 (en) * 2007-02-14 2008-08-21 Brigham And Women's Hospital, Inc. Crosslinked polymers and methods of making the same
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2008134807A1 (en) * 2007-05-04 2008-11-13 The University Of Sydney Method for manufacturing a porous polymer matrix
KR101513318B1 (ko) * 2007-05-14 2015-04-17 가부시키가이샤 엘티티 바이오파마 서방성의 음하전기를 갖는 저분자 약물 함유 나노 입자
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CA2713150C (en) 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
CN102123745A (zh) * 2008-02-29 2011-07-13 科洛普拉斯特公司 用于受试者中活组织的增加和再生的组合物和方法
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
AU2009244308A1 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
RU2518351C2 (ru) 2008-05-09 2014-06-10 Эббви Дойчланд Гмбх Унд Ко.Кг, Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
ES2770273T3 (es) 2008-06-27 2020-07-01 Tepha Inc Administración inyectable de micropartículas y composiciones para ello
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US20110218155A1 (en) 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
US20110212179A1 (en) * 2008-10-30 2011-09-01 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
EP2358748B1 (en) 2008-12-09 2016-07-06 Dana-Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2010085607A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Continuous double emulsion process for making microparticles
CN102369217A (zh) * 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
CN102573881A (zh) 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
WO2011025734A1 (en) 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
US8623358B2 (en) 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
AR078254A1 (es) * 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
EP2764871A1 (en) 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (en) * 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
US8916517B2 (en) 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
WO2011082324A1 (en) 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US20130190244A1 (en) 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011091357A1 (en) 2010-01-25 2011-07-28 Cornell University Aromatic-cationic peptides and uses of same
EP3511012A1 (en) 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
EP2547352A4 (en) 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
EP3290433A1 (en) 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EA201291181A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
JP6319738B2 (ja) 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2688579A4 (en) 2011-03-24 2015-10-21 Univ Cornell CATIONIC AROMATIC PEPTIDES AND USES THEREOF
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
RU2640025C2 (ru) 2011-07-13 2017-12-25 Эббви Инк. Способы и композиции для лечения астмы с использованием антител против il-13
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
BR112014006929A2 (pt) 2011-09-23 2017-04-04 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa agentes anti-fator de necrose tumoral-alfa e seus usos
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
CA2852454A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
EP2771360A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Immunobinders directed against sclerostin
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
JP2015500829A (ja) 2011-12-05 2015-01-08 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
EP3466439A1 (en) 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN104144947B (zh) 2011-12-14 2017-10-27 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
EP2791175A2 (en) 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP2817018A4 (en) 2012-02-22 2015-09-23 Stealth Peptides Int Inc METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
AU2013222237B2 (en) 2012-02-23 2017-10-05 Cornell University Aromatic-cationic peptides and uses of same
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
JP2015524439A (ja) 2012-08-02 2015-08-24 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
ES3058737T3 (en) 2012-10-22 2026-03-12 Stealth Biotherapeutics Inc Treatment of left ventricular remodeling
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
KR20150082503A (ko) 2012-11-09 2015-07-15 화이자 인코포레이티드 혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
EP3459598A1 (en) 2012-12-06 2019-03-27 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
JP2016509582A (ja) 2012-12-19 2016-03-31 アンプリミューン， インコーポレイテッド 抗ヒトｂ７−ｈ４抗体およびその使用
BR112015014621A2 (pt) 2012-12-21 2017-10-03 Amplimmune Inc Anticorpos anti-h7cr
CA2900755C (en) 2013-02-08 2021-07-20 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
ES2750258T3 (es) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Métodos y composiciones para la prevención o tratamiento del síndrome de Barth
CN117752766A (zh) 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970947A4 (en) 2013-03-14 2016-10-12 Abbott Lab RECOMBINANT HCV NS3 ANTIGENS AND THEIR MUTANTS FOR ENHANCED ANTIBODY DETECTION
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
JP2016514130A (ja) 2013-03-14 2016-05-19 ノバルティス アーゲー Ｎｏｔｃｈ３に対する抗体
BR112015021134A2 (pt) 2013-03-15 2017-10-10 Novartis Ag conjugados de fármaco e anticorpo
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
CN105579054A (zh) 2013-05-14 2016-05-11 康德生物医疗技术公司 预防或治疗左心室重塑的方法
MX376808B (es) 2013-05-24 2025-03-07 Medimmune Llc Anticuerpos anti-b7-h5 y sus usos.
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
CA2916486A1 (en) 2013-06-26 2015-01-22 Stealth Biotherapeutics Corp Methods and compositions comprising an aromatic peptide for regulating serca2a expression levels in myocardinal infarction
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160166633A1 (en) 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
JP2016533318A (ja) 2013-09-17 2016-10-27 ユニバーシティ ヘルス ネットワーク （ユーエイチエヌ）： テクノロジー ディベロップメント アンド コマーシャリゼーション Ｒｇｍａ／ネオジェニンのシス相互作用又は脂質ラフトを標的とする剤及び治療方法における該剤の使用
WO2015058868A1 (en) 2013-10-25 2015-04-30 Pangaea Biotech, S.L. Compositions and methods for the treatment of cancer
US10287572B2 (en) 2013-11-01 2019-05-14 Regents Of The University Of Minnesota Protein scaffolds and methods of use
EP3068801A1 (en) 2013-11-13 2016-09-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015084883A2 (en) 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
JP2016540762A (ja) 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ 白斑の治療のための組成物及び方法
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
KR20160135190A (ko) 2014-02-14 2016-11-25 앤드류 에스. 카이 혈관형성 암의 치료를 위한 개선된 방법
EP3450571B1 (en) 2014-02-24 2023-04-05 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
CN106659800A (zh) 2014-03-12 2017-05-10 诺华股份有限公司 用于修饰抗体以制备免疫缀合物的特定位点
TW202214691A (zh) 2014-03-21 2022-04-16 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
CA2950410A1 (en) 2014-05-28 2015-12-03 D. Travis Wilson Therapeutic compositions including therapeutic small molecules and uses thereof
EP3501532A3 (en) 2014-05-28 2019-07-17 Stealth BioTherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
CA2951162C (en) 2014-06-04 2019-04-23 Tersus Pharmaceuticals, LLC Methods of treating chronic dry eye disease using c16:1n7-palmitoleate and derivatives thereof
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JP6755235B2 (ja) 2014-07-16 2020-09-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 低悪性度漿液性癌におけるｈｅｒ３阻害
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
PE20170903A1 (es) 2014-08-12 2017-07-12 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6
EP3182989B1 (en) 2014-08-21 2021-04-14 Stealth Biotherapeutics Corp Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome
AP2017009823A0 (en) 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
PE20170912A1 (es) 2014-11-14 2017-07-12 Novartis Ag Conjugados de anticuerpo-farmaco
EP3227319B1 (en) 2014-12-04 2019-11-27 Novartis AG Methods and compositions using klotho variant polypeptides
AU2015357549B2 (en) 2014-12-05 2022-03-24 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
EP3227440B1 (en) 2014-12-05 2021-07-14 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2016183532A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to treat a disease or disorder
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
WO2016118921A1 (en) 2015-01-24 2016-07-28 Abbvie, Inc. Compositions and methods for treating psoriatic arthritis
HK1247215A1 (zh) 2015-01-26 2018-09-21 Macrogenics, Inc. 包含dr5-结合结构域的多价分子
WO2016120828A1 (en) 2015-01-30 2016-08-04 Novartis Ag Treatment of breast cancer by m-csf antagonist
MX385397B (es) 2015-03-02 2025-03-18 Synlogic Operating Co Inc Bacteria manejada genéticamente para producir butirato, interleucina-10 y/o interleucina-22 para tratar enfermedades que se benefician de inflamación intestinal reducida y/o barrera mucosa intestinal fortalecida.
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
EP3294760B1 (en) 2015-05-13 2021-03-24 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP6817966B2 (ja) 2015-06-10 2021-01-20 シンロジック オペレーティング カンパニー インコーポレイテッド 高アンモニア血症に関連する疾患を治療するために操作された細菌
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
WO2017023818A1 (en) 2015-07-31 2017-02-09 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
CA2938576A1 (en) * 2015-08-12 2017-02-12 Howmedica Osteonics Corp. Methods for forming scaffolds
US11331191B2 (en) 2015-08-12 2022-05-17 Howmedica Osteonics Corp. Bioactive soft tissue implant and methods of manufacture and use thereof
US11273184B2 (en) 2015-08-31 2022-03-15 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
BR112018004867A2 (pt) 2015-09-11 2018-10-16 Abbvie Deutschland métodos para tratamento das formas recorrentes de esclerose múltipla
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
US10449259B2 (en) 2015-10-02 2019-10-22 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075485A1 (en) 2015-10-30 2017-05-04 Synlogic, Inc. Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
WO2017074566A1 (en) 2015-10-30 2017-05-04 Dean Falb Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017087580A1 (en) 2015-11-16 2017-05-26 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
CN116196389A (zh) 2016-01-06 2023-06-02 康德生物医疗有限公司 用于预防和治疗杜氏肌肉萎缩症的方法和组合物
WO2017123610A2 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to detoxify deleterious molecules
WO2017123592A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to treat disorders associated with bile salts
EP3405492B1 (en) 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
CN108472414A (zh) 2016-01-25 2018-08-31 史密夫和内修有限公司 矫形外科植入物
EP4356938A3 (en) 2016-05-02 2024-07-24 Howmedica Osteonics Corp. Bioactive soft tissue implant and methods of manufacture and use thereof
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
AU2017267969A1 (en) 2016-05-19 2018-12-13 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and treatment of mitochondrial myopathies
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
CA3027044A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
US11567082B2 (en) 2016-07-01 2023-01-31 Dana-Farber Cancer Institute, Inc. Compositions, assays, and methods for direct modulation of fatty acid metabolism
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
WO2018053405A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
KR20250036941A (ko) 2017-05-31 2025-03-14 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
EP3635007A1 (en) 2017-06-06 2020-04-15 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
AU2018290278B2 (en) 2017-06-21 2022-12-15 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
WO2019032717A1 (en) 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR
JP2020533408A (ja) 2017-09-08 2020-11-19 学校法人慶應義塾 炎症性腸疾患を制御するためのバクテリオファージ
BR112020010753A2 (pt) 2017-12-01 2020-11-24 The Regents Of The University Of California anticorpos anti-cxcr5 e composições e usos dos mesmos
CA3083363A1 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
CA3094756A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
CN112165974B (zh) 2018-05-31 2024-11-08 诺华股份有限公司 乙型肝炎抗体
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
EP3807321A4 (en) 2018-06-18 2022-03-02 Anwita Biosciences, Inc. ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
US12492250B2 (en) 2018-09-28 2025-12-09 Emory University suPAR and prediction and treatment of acute kidney injury
US11931397B2 (en) 2018-12-06 2024-03-19 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of Sengers syndrome
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
PH12021551479A1 (en) 2018-12-21 2022-07-18 Novartis Ag Antibodies to pmel17 and conjugates thereof
CN113891721A (zh) 2019-03-07 2022-01-04 学校法人庆应义塾 用于调节炎症性肠病的噬菌体
KR102563319B1 (ko) 2019-03-08 2023-08-03 앱티스 주식회사 위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
WO2020205827A1 (en) 2019-04-01 2020-10-08 Rush University Medical Center Reagents and assays using modified integrin domains
TW202102526A (zh) 2019-04-04 2021-01-16 美商銳進科斯生物股份有限公司 重組腺相關病毒及其用途
EP3963046A1 (en) 2019-04-29 2022-03-09 Synlogic Operating Company, Inc. Enumeration of genetically engineered microorganisms by live cell counting techniques
WO2020226710A1 (en) * 2019-05-07 2020-11-12 Ut-Battelle, Llc Toughened polyester composites containing polyester matrix and droplets of high boiling liquid therein
US20220251179A1 (en) 2019-05-28 2022-08-11 Shanghaitech University Composition and methods to treat ectodermal dysplasia 2, clouston type
PT3986401T (pt) 2019-07-24 2026-02-03 Stealth Biotherapeutics Inc Composto peptidomimético (r)-2-amino-n-((s)-l-(((s)-5- amino-l-(3-benzil-1,2,4-oxadiazol-5-il)pentil)amino)-3-(4- hidroxi-2,6-dimetilfenil)-1-oxopropan-2-il)-5- guanidinopentanamida no tratamento de doenças neurodegenerativas
EP4004214A1 (en) 2019-07-26 2022-06-01 RegenxBio Inc. Engineered nucleic acid regulatory element and methods of uses thereof
EP4014047B1 (en) 2019-08-14 2025-11-19 Memorial Sloan Kettering Cancer Center Ogdh inhibitors for use in the treatment of cancer
MX2022002949A (es) 2019-09-24 2022-04-06 Prolacta Bioscience Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes.
CN114729045B (zh) 2019-09-26 2025-09-09 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
IL291898A (en) 2019-10-04 2022-06-01 Stealth Biotherapeutics Inc Quinone-, hydroquinone- and naphthoquinone-analogues of vatiquinone for treatment of mitochondrial disorder diseases
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
JP2023518184A (ja) 2020-03-20 2023-04-28 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するように遺伝子改変された微生物
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
WO2021202986A1 (en) 2020-04-03 2021-10-07 Stealth Biotherapeutics Corp Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN116157510A (zh) 2020-06-17 2023-05-23 詹森生物科技公司 用于制造多能干细胞的材料和方法
WO2022012680A1 (en) 2020-07-16 2022-01-20 Nanjing Legend Biotech Co., Ltd. Cd20 binding molecules and uses thereof
WO2022031576A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
CA3190987A1 (en) 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
AU2021356667A1 (en) 2020-10-07 2023-06-08 Regenxbio Inc. Adeno-associated viruses for ocular delivery of gene therapy
WO2022076750A2 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Recombinant adeno-associated viruses for cns or muscle delivery
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
AU2021374083A1 (en) 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
AU2021393455A1 (en) 2020-12-02 2023-06-29 Synlogic Operating Company, Inc. Engineered microorganisms
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
CN116847860A (zh) 2020-12-31 2023-10-03 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
KR20230131228A (ko) 2021-01-12 2023-09-12 프롤랙타 바이오사이언스, 인코포레이티드 신바이오틱 치료 요법
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20240191176A1 (en) 2021-04-13 2024-06-13 Synlogic Operating Company, Inc. Bacteria engineered to secrete active proteins
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
EP4351547A4 (en) 2021-06-10 2025-05-14 Stealth BioTherapeutics Inc. Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
CA3226019A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023044479A1 (en) 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia
EP4413018A1 (en) 2021-10-07 2024-08-14 RegenxBio Inc. Recombinant adeno-associated viruses for targeted delivery
EP4413019A2 (en) 2021-10-07 2024-08-14 RegenxBio Inc. Recombinant adeno-associated viruses for cns tropic delivery
WO2023069255A1 (en) 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023077092A1 (en) 2021-10-28 2023-05-04 Regenxbio Inc. Engineered nucleic acid regulatory elements and methods and uses thereof
CN118119642A (zh) 2021-10-28 2024-05-31 诺华股份有限公司 工程化Fc变体
US20250027084A1 (en) 2021-11-30 2025-01-23 Northwestern University Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
AU2023205058A1 (en) 2022-01-10 2024-07-25 Stealth Biotherapeutics Inc. Small molecule peptidomimetic for the treatment of tauopathies
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
CA3251397A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. METHODS AND COMPOSITIONS COMPRISING COMPONENTS FOR BRINGING BISORPOSE VΒ17 T LYMPHOCYTES TO CONTACT WITH BIOMODIFIED VIRUS-SPECIFIC LYMPHOCYTES
WO2023178053A1 (en) 2022-03-13 2023-09-21 Regenxbio Inc. Modified muscle-specific promoters
WO2023201277A1 (en) 2022-04-14 2023-10-19 Regenxbio Inc. Recombinant adeno-associated viruses for cns tropic delivery
US20250249127A1 (en) 2022-04-14 2025-08-07 Regenxbio Inc. Gene therapy for treating an ocular disease
US20250277004A1 (en) 2022-04-18 2025-09-04 Regenxbio Inc. Hybrid aav capsids
WO2023209568A1 (en) 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2023245171A1 (en) 2022-06-17 2023-12-21 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
WO2023245168A1 (en) 2022-06-17 2023-12-21 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
EP4543470A1 (en) 2022-06-23 2025-04-30 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
EP4554969A1 (en) 2022-07-15 2025-05-21 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
US20250188492A1 (en) 2022-07-22 2025-06-12 Janssen Biotech, Inc. Enhanced Transfer of Genetic Instructions to Effector Immune Cells
CA3263784A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. TRANSFERRIN RECEPTOR BINDING PROTEINS FOR THE TREATMENT OF BRAIN TUMORS
JP2025525969A (ja) 2022-08-05 2025-08-07 ヤンセン バイオテツク，インコーポレーテツド 脳腫瘍を治療するためのｃｄ９８結合構築物
US20260055144A1 (en) 2022-08-24 2026-02-26 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
JP2025534666A (ja) 2022-10-11 2025-10-17 リジェネックスバイオ インコーポレイテッド 操作された核酸調節エレメントならびにその使用方法
WO2024081768A1 (en) 2022-10-12 2024-04-18 Synlogic Operating Company, Inc. Bacteria engineered to produce active epidermal growth factor (egf) and their medical uses
EP4605522A1 (en) 2022-10-17 2025-08-27 Synlogic Operating Company, Inc. Recombinant bacteria expressing phenylalanine ammonia lyase, phenylalanine transporter and l- aminoacid deaminase for reducing hyperphenylalaninemia
EP4608424A1 (en) 2022-10-24 2025-09-03 AGS Therapeutics SAS Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024129974A1 (en) 2022-12-14 2024-06-20 Synlogic Operating Company, Inc. Recombinant bacteria for use in the treatment of disorders in which oxalate is detrimental
WO2024130119A2 (en) 2022-12-16 2024-06-20 Prolacta Bioscience, Inc. Synbiotic compositions for short chain fatty acid production
TW202448505A (zh) 2023-03-01 2024-12-16 美商普泛森生技公司 用於治療第1型糖尿病的方法及組成物
WO2024194423A1 (en) 2023-03-23 2024-09-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their use for vaccines and for immunomodulation
TW202506177A (zh) 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法
WO2024216244A2 (en) 2023-04-13 2024-10-17 Regenxbio Inc. Targeting aav capsids, methods of manufacturing and using same
WO2024238853A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Adeno-associated viruses for ocular delivery of gene therapy
AU2024299422A1 (en) 2023-07-27 2026-03-12 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
WO2025101748A1 (en) 2023-11-09 2025-05-15 Stealth Biotherapeutics Inc. Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy
WO2025108407A2 (en) 2023-11-23 2025-05-30 Neuexcell Therapeutics (Suzhou) Co., Ltd. Gene therapy compositions and methods for treating glioma
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles
WO2025217214A2 (en) 2024-04-08 2025-10-16 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
WO2025231245A1 (en) 2024-05-02 2025-11-06 Stealth Biotherapeutics Inc. Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies
WO2026020091A1 (en) 2024-07-19 2026-01-22 Stealth Biotherapeutics Inc. Methods, compounds, compositions, formulations and uses for addressing mitochondrial disease resulting from nuclear dna mutations
US20260048096A1 (en) 2024-08-19 2026-02-19 Stealth Biotherapeutics Inc. Methods and compositions for preserving the retinal outer nuclear layer (onl), photoreceptors, and retinal thickness
WO2026058155A1 (en) 2024-09-11 2026-03-19 Novartis Ag Antibodies targeting il-31
CN121896173A (zh) 2024-10-21 2026-04-21 深圳市湾岛细胞科技有限公司 表达外源肌苷单磷酸脱氢酶的真核细胞

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (pt) * 1972-01-26 1977-01-27
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
WO1989003678A1 (en) * 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
WO1989005138A1 (en) * 1987-12-08 1989-06-15 Mark Chasin Method of forming bioerodible implants for improved controlled drug release
DE3744329A1 (de) 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
DK0432232T3 (da) * 1989-05-01 1994-01-31 Alkermes Inc Fremgangsmåde til fremstilling af små partikler af biologisk aktive molekyler
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5232707A (en) * 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
EP0452111B1 (en) * 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
DE4041563A1 (de) 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
ZA93929B (en) * 1992-02-18 1993-09-10 Akzo Nv A process for the preparation of biologically active materialcontaining polymeric microcapsules.
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
IT1255792B (it) 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
DK0674506T3 (da) * 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
US5307640A (en) 1993-01-25 1994-05-03 E. I. Du Pont De Nemours And Company Apparatus and method for producing frozen particles of a liquid
JPH06323712A (ja) 1993-04-20 1994-11-25 E I Du Pont De Nemours & Co 霧化した極低温液滴の閉じ込め帯域を用いて凍結粒子を製造する方法および装置
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices

Also Published As

Publication number Publication date
DK1017367T3 (da) 2003-09-22
DE69814885T2 (de) 2004-05-19
US6455074B1 (en) 2002-09-24
DE69814885D1 (de) 2003-06-26
ES2200375T3 (es) 2004-03-01
CA2304662C (en) 2007-09-18
ATE240718T1 (de) 2003-06-15
EP1017367B1 (en) 2003-05-21
JP2001517615A (ja) 2001-10-09
EP1017367A1 (en) 2000-07-12
CA2304662A1 (en) 1999-04-01
US5989463A (en) 1999-11-23
AU746337B2 (en) 2002-04-18
AU9400998A (en) 1999-04-12
WO1999015154A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
DK1017367T3 (da) Fremgangsmåder til fremstilling af polymerbaserede frigivelsespræparater
HUP0004732A2 (hu) Kapszulázási eljárás
ES2077575T3 (es) Procedimiento para la preparacion de polifenilen-eter modificado o polimeros relacionados y su uso en polimeros rigidos a alta temperatura, modificados, de compuestos aromaticos sustituidos con vinilo.
ATE221773T1 (de) Formulierungen mit gesteuerter freisetzung
PT729353E (pt) Preparacao de microparticulas biodegradaveis contendo um agente biologicamente activo
DE69315026D1 (de) Verfahren zur Herstellung einer Zubereitung von Mikrosphären mit verzögerter Freigabe
DK0460185T3 (da) Fremstilling af farmaceutiske og andre matrixsystemer ved opløsning i fast tilstand
BR0009487A (pt) Micropartìculas com ligações cruzadas, processo para preparação e usos destas
DE69714448D1 (de) Verfahren zur herstellung von präparaten mit kontrollierter wirkstofffreisetzung auf basis von polymeren
WO1998007318A3 (en) Method of making controlled release devices
WO1998027962A3 (en) Injectable depot gel composition and method of preparing the composition
DE59610087D1 (de) Verfahren zur Modifizierung von Dispersionspulver-Zusammensetzungen
EP1898881A4 (en) BIORESORBABLE POLYMERMATRICES AND METHOD FOR THEIR PREPARATION AND USE
GB2327042A (en) Improved preparation method for biodegradable polymeric microspheres using solvent extraction and preparation method for microspheres
DE69835232D1 (de) Nichtwässriges, heterogenes polymerisationsverfahren und dadurch erhaltenes reaktionsprodukt
WO2003095583A1 (en) Thickener, cosmetic preparation containing the same, and process for producing the same
WO2002085960A3 (en) Alpha olefin monomer partitioning agents for drag reducing agents and methods of forming drag reducing agents using alpha olefin monomer partitioning agents
AU4068201A (en) Process for the preparation of accelerated release formulations using compressedfluids
KR960030931A (ko) 피부 약물 전달 체계용 에멀젼 네트웍의 제조방법
BR0114938B1 (pt) processo para a produção de um copolìmero de enxerto.
HK1049113A1 (zh) 含新红血球生成的刺激性蛋白质的生物所能分解的微粒子
ES2078182A1 (es) Procedimiento para la preparacion de microesferas biodegradables con liberacion controlada y microesferas correspondientes.
ATE136312T1 (de) Verfahren zur herstellung von vernetztem polybeta-alanin in einem einzigen schritt aus acrylamid und einer polyfunktionalen copolymerisierbaren verbindung
DK1722761T3 (da) Fremgangsmåde til frembringelse af mikropartikler
AU3954497A (en) Support with super-absorbent material, method for the preparation thereof and use